IP Verse

Human Anti-Il-23 Antibodies, Compositions, Method And Uses - EP3219328

The patent EP3219328 was granted to Janssen Biotech on Jun 17, 2020. The application was originally filed on Dec 28, 2006 under application number EP17156111A. The patent is currently recorded with a legal status of "Revoked".

EP3219328

JANSSEN BIOTECH
Application Number
EP17156111A
Filing Date
Dec 28, 2006
Status
Revoked
Mar 19, 2021
Grant Date
Jun 17, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ABBVIEMar 17, 2021KONIG SZYNKA TILMANN VON RENESSE DUSSELDORFDEEMED NOT TO HAVE BEEN FILED
ABBVIEMar 17, 2021KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFDEEMED NOT TO HAVE BEEN FILED
BOEHRINGER INGELHEIM PHARMAMar 17, 2021HOFFMANN EITLEDEEMED NOT TO HAVE BEEN FILED

Patent Citations (175) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS19920943852-
DESCRIPTIONUS19950442133-
DESCRIPTIONWO1989GB01334-
DESCRIPTIONWO1991GB01134-
DESCRIPTIONWO1991US05939-
DESCRIPTIONWO1991US09630-
DESCRIPTIONWO1992GB01755-
DESCRIPTIONWO1994US01234-
DESCRIPTIONWO1996US18978-
DESCRIPTIONWO1998US16280-
DESCRIPTIONEP0003089
DESCRIPTIONEP0218868
DESCRIPTIONEP0229246
DESCRIPTIONEP0237507
DESCRIPTIONEP0288088
DESCRIPTIONUS2003003097
DESCRIPTIONUS3773919
DESCRIPTIONUS4239754
DESCRIPTIONUS4309989
DESCRIPTIONUS4399216
DESCRIPTIONUS4589330
DESCRIPTIONUS4634665
DESCRIPTIONUS4656134
DESCRIPTIONUS4668218
DESCRIPTIONUS4676980
DESCRIPTIONUS4683195
DESCRIPTIONUS4683202
DESCRIPTIONUS4704692
DESCRIPTIONUS4766067
DESCRIPTIONUS4767402
DESCRIPTIONUS4795699
DESCRIPTIONUS4800159
DESCRIPTIONUS4816567
DESCRIPTIONUS4818542
DESCRIPTIONUS4873316
DESCRIPTIONUS4889818
DESCRIPTIONUS4921794
DESCRIPTIONUS4925673
DESCRIPTIONUS4939666
DESCRIPTIONUS4946778
DESCRIPTIONUS4956288
DESCRIPTIONUS4965188
DESCRIPTIONUS4994370
DESCRIPTIONUS5066584
DESCRIPTIONUS5091310
DESCRIPTIONUS5116964
DESCRIPTIONUS5122464
DESCRIPTIONUS5130238
DESCRIPTIONUS5142033
DESCRIPTIONUS5149636
DESCRIPTIONUS5168062
DESCRIPTIONUS5179017
DESCRIPTIONUS5223409
DESCRIPTIONUS5225538
DESCRIPTIONUS5225539
DESCRIPTIONUS5231024
DESCRIPTIONUS5260203
DESCRIPTIONUS5266491
DESCRIPTIONUS5304489
DESCRIPTIONUS5385839
DESCRIPTIONUS5403484
DESCRIPTIONUS5404871
DESCRIPTIONUS5427908
DESCRIPTIONUS5447851
DESCRIPTIONUS5455030
DESCRIPTIONUS5458135
DESCRIPTIONUS5496549
DESCRIPTIONUS5514670
DESCRIPTIONUS5518889
DESCRIPTIONUS5530101
DESCRIPTIONUS5534621
DESCRIPTIONUS5565362
DESCRIPTIONUS5571698
DESCRIPTIONUS5576195
DESCRIPTIONUS5580717
DESCRIPTIONUS5580734
DESCRIPTIONUS5582996
DESCRIPTIONUS5585089
DESCRIPTIONUS5595898
DESCRIPTIONUS5601819
DESCRIPTIONUS5618920
DESCRIPTIONUS5641670
DESCRIPTIONUS5643759
DESCRIPTIONUS5643768
DESCRIPTIONUS5656730
DESCRIPTIONUS5658754
DESCRIPTIONUS5693493
DESCRIPTIONUS5693762
DESCRIPTIONUS5698417
DESCRIPTIONUS5698435
DESCRIPTIONUS5714352
DESCRIPTIONUS5723323
DESCRIPTIONUS5733746
DESCRIPTIONUS5733761
DESCRIPTIONUS5750373
DESCRIPTIONUS5763192
DESCRIPTIONUS5763733
DESCRIPTIONUS5766886
DESCRIPTIONUS5767260
DESCRIPTIONUS5770222
DESCRIPTIONUS5770359
DESCRIPTIONUS5807706
DESCRIPTIONUS5814476
DESCRIPTIONUS5814599
DESCRIPTIONUS5817483
DESCRIPTIONUS5821333
DESCRIPTIONUS5824514
DESCRIPTIONUS5827690
DESCRIPTIONUS5827739
DESCRIPTIONUS5833985
DESCRIPTIONUS5837500
DESCRIPTIONUS5839446
DESCRIPTIONUS5849695
DESCRIPTIONUS5849992
DESCRIPTIONUS5851198
DESCRIPTIONUS5856456
DESCRIPTIONUS5871753
DESCRIPTIONUS5879681
DESCRIPTIONUS5885793
DESCRIPTIONUS5932448
DESCRIPTIONUS5959083
DESCRIPTIONUS5959084
DESCRIPTIONUS5976862
DESCRIPTIONUS5989530
DESCRIPTIONUS5994616
DESCRIPTIONUS6010902
DESCRIPTIONUS6019968
DESCRIPTIONUS6037453
DESCRIPTIONUS6060285
DESCRIPTIONUS6106833
DESCRIPTIONUS6132992
DESCRIPTIONUS6180370
DESCRIPTIONUS6193967
DESCRIPTIONUS6204023
DESCRIPTIONUS6210668
DESCRIPTIONUS6309663
DESCRIPTIONWO0042072
DESCRIPTIONWO03011878
DESCRIPTIONWO2005005604
DESCRIPTIONWO9014424
DESCRIPTIONWO9014430
DESCRIPTIONWO9014443
DESCRIPTIONWO9100360
DESCRIPTIONWO9102078
DESCRIPTIONWO9117271
DESCRIPTIONWO9118980
DESCRIPTIONWO9119818
DESCRIPTIONWO9200373
DESCRIPTIONWO9205258
DESCRIPTIONWO9207076
DESCRIPTIONWO9214843
DESCRIPTIONWO9216221
DESCRIPTIONWO9308278
DESCRIPTIONWO9308829
DESCRIPTIONWO9406498
DESCRIPTIONWO9408552
DESCRIPTIONWO9416970
DESCRIPTIONWO9619256
DESCRIPTIONWO9722376
DESCRIPTIONWO9725086
DESCRIPTIONWO9835888
DESCRIPTIONWO9853847
DESCRIPTIONWO9916419
DESCRIPTIONWO9954342
OPPOSITIONEP1896073
OPPOSITIONUS6495667
OPPOSITIONWO2004081190
OPPOSITIONWO2005052157
OPPOSITIONWO2005108425
OPPOSITIONWO2007005955
OPPOSITIONWO2007024846
OPPOSITIONWO2007027714
OPPOSITIONWO2007076524
SEARCHUS2004223969
SEARCHWO2005108425

Non-Patent Literature (NPL) Citations (106) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ASHKENAZI ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 10535 - 10539-
DESCRIPTION- BAKER ET AL., EUR. J. IMMUNOL., (1994), vol. 24, pages 2040 - 2048-
DESCRIPTION- BRINGMAN ET AL., HYBRIDOMA, (1987), vol. 6, pages 489 - 507-
DESCRIPTION- BUTLER ET AL., CYTOKINE, (1994), vol. 6, no. 6, pages 616 - 623-
DESCRIPTION- CAPELLAS ET AL., BIOTECHNOL. BIOENG., (1997), vol. 56, no. 4, pages 456 - 463-
DESCRIPTION- CAPON ET AL., NATURE, (1989), vol. 337, pages 525 - 531-
DESCRIPTION- CARTER ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1992), vol. 89, page 4285-
DESCRIPTION- CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, page 901-
DESCRIPTION- CONRAD ET AL., PLANT MOL. BIOL., (1998), vol. 38, pages 101 - 109-
DESCRIPTION- CORCORAN ET AL., EUR. J. BIOCHEM., (1994), vol. 223, pages 831 - 840-
DESCRIPTION- CRAMER ET AL., CURR. TOP. MICROBOL. IMMUNOL., (1999), vol. 240, pages 95 - 118-
DESCRIPTION- CUNNINGHAM; WELLS, SCIENCE, (1989), vol. 244, pages 1081 - 1085-
DESCRIPTION- DE JONGH ET AL., J. INVEST DERMATOL, (2005), vol. 125, pages 1163 - 1173-
DESCRIPTION- DE VOS ET AL., SCIENCE, (1992), vol. 255, pages 306 - 312-
DESCRIPTION- ENGELMANN, H. ET AL., J. BIOL. CHEM., (1990), vol. 265, pages 1531 - 1536-
DESCRIPTION- EVANS ET AL.,, Bacterial Infections of Humans: Epidemiology and Control, 2nd ed.,, PLENUM MEDICAL BOOK CO., (1991), pages 239 - 254-
DESCRIPTION- FENDLY ET AL., HYBRIDOMA, (1987), vol. 6, pages 359 - 369-
DESCRIPTION- FISCHER ET AL., BIOTECHNOL. APPL. BIOCHEM., (199910), vol. 30, pages 99 - 108-
DESCRIPTION- FISCH ET AL., BIOCONJUGATE CHEM., (1992), vol. 3, pages 147 - 153-
DESCRIPTION- HIRAI ET AL., J. IMMUNOL. METH., (1987), vol. 96, pages 57 - 62-
DESCRIPTION- HOOD ET AL., ADV. EXP. MED. BIOL., (1999), vol. 464, pages 127 - 147-
DESCRIPTION- INTERNAL MEDICINE, 3rd ed.,, LITTLE, BROWN AND CO., (1990), pages 1 - 13-
DESCRIPTION- ITOH ET AL., BIOORG. CHEM., (1996), vol. 24, no. 1, pages 59 - 68-
DESCRIPTION- JONES ET AL., NATURE, (1986), vol. 321, page 522-
DESCRIPTION- JUNGINGER ET AL., Drug Permeation Enhancement, MARCEL DEKKER, INC., (1994), pages 59 - 90-
DESCRIPTION- KOLLS ET AL., PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, pages 215 - 219-
DESCRIPTION- KUMARAN ET AL., PROTEIN SCI., (1997), vol. 6, no. 10, pages 2233 - 2241-
DESCRIPTION- LESSLAUER ET AL., EUR. J. IMMUNOL., (1991), vol. 21, pages 2883 - 2886-
DESCRIPTION- LIANG ET AL., BIOCHEM. BIOPHYS. RES. COMM., (1986), vol. 137, pages 847 - 854-
DESCRIPTION- LOETSCHER ET AL., CELL, (1990), vol. 61, pages 351 - 359-
DESCRIPTION- MA ET AL., PLANT PHYSIOL., (1995), vol. 109, pages 341 - 6-
DESCRIPTION- MA ET AL., TRENDS BIOTECHNOL., (1995), vol. 13, pages 522 - 7-
DESCRIPTION- MARRACK ET AL., SCIENCE, (1990), vol. 248, pages 705 - 711-
DESCRIPTION- MEAGER ET AL., HYBRIDOMA, (1987), vol. 6, pages 305 - 311-
DESCRIPTION- MILSTEIN; CUELLO, NATURE, (1983), vol. 305, page 537-
DESCRIPTION- MOLLER, A. ET AL., CYTOKINE, (1990), vol. 2, no. 3, pages 162 - 169-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 1041 - 97-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 1098 - 1136-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 1137 - 63-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 215 - 336-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 24 - 214-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 337 - 530-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 531 - 84-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 585 - 642-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 643 - 95-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 696 - 796-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 797 - 833-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 834 - 66-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 867 - 963-
DESCRIPTION- Nursing 2001 Drug Handbook, (2001), pages 964 - 1040-
DESCRIPTION- PEPPEL ET AL., J. EXP. MED., (1991), vol. 174, pages 1483 - 1489-
DESCRIPTION- PRESTA ET AL., J. IMMUNOL., (1993), vol. 151, page 2623-
DESCRIPTION- RIECHMANN ET AL., NATURE, (1988), vol. 332, page 323-
DESCRIPTION- SCHALL ET AL., CELL, (1990), vol. 61, pages 361 - 370-
DESCRIPTION- SHIELDS ET AL., "High resolution mapping of the binding site on human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and design of IgGl variants with improved binding to the FcyR", J. BIOL. CHEM., (2001), vol. 276, pages 6591 - 6604-
DESCRIPTION- SIMS ET AL., J. IMMUNOL., (1993), vol. 151, page 2296-
DESCRIPTION- SMITH ET AL., J. MOL. BIOL., (1992), vol. 224, pages 899 - 904-
DESCRIPTION- SPRAGUE ET AL., J. VIROL., (1983), vol. 45, pages 773 - 781-
DESCRIPTION- SURESH ET AL., METHODS IN ENZYMOLOGY, (1986), vol. 121, page 210-
DESCRIPTION- TRAUNECKER ET AL., EMBO J., (1991), vol. 10, page 3655-
DESCRIPTION- UMANA ET AL., NATURE BIOTECHNOLOGY, (199902), vol. 17, pages 176 - 180-
DESCRIPTION- VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, page 1534-
DESCRIPTION- WELLS ET AL.,, Pharmcotherapy Handbook, APPLETON & LANGE-
DESCRIPTION- WERLEN ET AL., BIOCONJUGATE CHENZ., (1994), vol. 5, pages 411 - 417-
DESCRIPTION- WHITELAM ET AL., BIOCHEM. SOC. TRANS., (1994), vol. 22, pages 940 - 944-
DESCRIPTION- WOOD ET AL., FEMS MICROBIOLOGY IMMUNOLOGY, (1991), vol. 76, pages 121 - 134-
DESCRIPTION- WRONE-SMITH ET AL., "Dermal injection of immunocytes induces psoriasis", J. CLIN. INVEST., (1996), vol. 98, doi:doi:10.1172/JCI118989, pages 1878 - 1887, XP002188300
DESCRIPTION- HOOGENBOOM HR, "Overview of antibody phage-display technology and its applications", METHODS IN MOLECULAR BIOLOGY., (2002), vol. 178, doi:doi:10.1385/1-59259-240-6:001, pages 1 - 37, XP009065679
OPPOSITION- Anonymous, "Anti-human IL-23 p19 Antibody", R&D Systems Inc., (20031217), R&D Systems Inc., (20221003), XP055967177-
OPPOSITION- Anonymous, "Anti-human IL-23 p19 Antibody", R & D Systems - MAB1290, (20060113), pages 1 - 2, R & D Systems - MAB1290, (20221004), XP055967490-
OPPOSITION- Anonymous, "Anti-human IL-23 p19 Antibody", R & D Systems - MAB1290, pages 1 - 2, R & D Systems - MAB1290, (20221004), XP055967490-
OPPOSITION- Anonymous, "Anti-Mouse IL-23 p19 Purified", eBioscience, (20100101), eBioscience, (20221003), XP055967167-
OPPOSITION- Anonymous, "Mouse IL-23 ELISA Ready-SET-Go! ELISA kit", eBioscience, (20091124), pages 1 - 6, eBioscience, (20221003), XP055253617-
OPPOSITION- Anonymous, "Quantikine Human RAGE", R&D Systems Inc., pages 1 - 10, R&D Systems Inc., (20221003), XP055253631-
OPPOSITION- Anonymous, "Table of contents", J. Inmunology, (20051215), vol. 175, no. 12, XP055967484-
OPPOSITION- Ebioscience, Inc., "Mouse IL-23 ELISA Ready-SET-GO! ELISA Kit ", eBioscience catalog number 88-7923, (20091124), XP055253617-
OPPOSITION- HÖLSCHER, "Targeting IL -23 in autoimmunity", Current Opinion in Investigational drugs, (20050000), vol. 6, no. 5, pages 489 - 495, XP008085031-
OPPOSITION- HÖLSCHER, "Targeting IL -23 in autoimmunity", Curr Opin Invest Drug s, (20050000), vol. 6, no. 5, pages 489 - 495, XP008085031-
OPPOSITION- "IL-23 p19 [Homo Sapiens]", Protein, (20031003), Database accession no. AAQ89442, URL: ncbi, XP055967169-
OPPOSITION- Nelson P. N., G M Reynolds, E E Waldron, E Ward, K Giannopoulos, P G Murray, "Monoclonal antibodies", J Clin Pathol: Mol Pathol, (20000601), vol. 53, no. 3, pages 111 - 117, XP055967155-
OPPOSITION- R&d Systems, Inc., "Quantikine Human RAGE", De Novo Catalogue, (20040301), pages 1 - 10, XP055253631-
OPPOSITION- Who, "International Nonproprietary Names for Pharmaceutical Substances (INN) Recommended List 71", WHO Drug Information, (20140101), vol. 28, pages 71 - 122, XP055967170-
OPPOSITION- M H Van Regenmortel, "What is a B-cell epitope?", M H Van Regenmortel, Mike Schutkowski, Ulrich Reineke (eds.), Epitope Mapping Protocols : Second Edition; IN: Methods in Molecular Biology; ISSN 1064-3745; Vol. 524, US , Humana Press , (20090101), vol. 524, pages 3 - 20, doi:10.1007/978-1-59745-450-6_1, ISBN 978-1-59745-450-6, XP055642505
OPPOSITION- BARRIE et al., "The interleukin-12 family of cytokines: Therapeuti c", Clinical and Applied Immunology Reviews, (20050000), vol. 5, doi:10.1016/j.cair.2005.06.003, pages 225 - 240, XP005096030
OPPOSITION- BARRIE et al., "The interleukin-12 family of cytokines: Therapeutic targets for inflammatory disease mediation", Clin Appl Immunol Rev, (20050000), vol. 5, doi:10.1016/j.cair.2005.06.003, pages 225 - 240, XP005096030
OPPOSITION- BELLADONNA, "IL -23 neutralization protects mice from Gram-negative endotoxic shock", Cytokine, (20060000), vol. 34, doi:10.1016/j.cyto.2006.04.011, pages 161 - 169, XP024907660
OPPOSITION- Presta, L.G., "Selection, design, and engineering of therapeutic antibodies", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20051001), vol. 116, no. 4, doi:10.1016/j.jaci.2005.08.003, ISSN 0091-6749, pages 731 - 736, XP005094459
OPPOSITION- PRESTA, "Selection, design, and engineering of therapeutic antibodies", J Allergy Clin Immunol, (20050000), vol. 116, doi:10.1016/j.jaci.2005.08.003, pages 731 - 736, XP005094459
OPPOSITION- Beyer, B.M. ; Ingram, R. ; Ramanathan, L. ; Reichert, P. ; Le, H.V. ; Madison, V. ; Orth, P., "Crystal Structures of the Pro-Inflammatory Cytokine Interleukin-23 and Its Complex with a High-Affinity Neutralizing Antibody", Journal of Molecular Biology, Academic Press, United Kingdom, United Kingdom , (20081017), vol. 382, no. 4, doi:10.1016/j.jmb.2008.08.001, ISSN 0022-2836, pages 942 - 955, XP026805072
OPPOSITION- BEYER et al., "Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody", J. Mol. Biol., vol. 382, doi:10.1016/j.jmb.2008.08.001, pages 942 - 955, XP026805072
OPPOSITION- OPPMANN B, ET AL., "Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20001101), vol. 13, no. 5, doi:10.1016/S1074-7613(00)00070-4, ISSN 1074-7613, pages 715 - 725, XP002903120
OPPOSITION- CUA et al., "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain", Nature, (20030200), vol. 421, doi:10.1038/nature01355, XP002971969
OPPOSITION- CUA, "lnterleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain", Nature, (20030000), vol. 421, doi:10.1038/nature01355, pages 744 - 748, XP002971969
OPPOSITION- HOOGENBOOM, "Selecting and screening recombinant antibody libraries", Nat Biotechnol, (20050000), vol. 23, no. 9, doi:10.1038/nbt1126, pages 1105 - 1116, XP002348401
OPPOSITION- MURPHY et al., "Divergent Pro- and Antiinflammatory Roles for IL -23 and IL -12 in Joint Autoimmune Inflammation", J. Exp. Med., (20030000), vol. 198, no. 12, doi:10.1084/jem.20030896, XP002294202
OPPOSITION- BOWMAN et al., "Rationale and safety of anti-interleukin-23 and anit-interleukin-17A therapy", Curr Opin Infect Dis, (20060000), vol. 19, doi:10.1097/01.qco.0000224818.42729.67, pages 245 - 252, XP009096913
OPPOSITION- BOWMAN et al., "Rationale and safety of anti-interleukin-23 and anti-interleukin- 17A therapy", Curr Opin Infect Dis, (20060000), vol. 19, doi:10.1097/01.qco.0000224818.42729.67, pages 245 - 252, XP009096913
OPPOSITION- LANGRISH C L,ET AL, "IL-12 and IL-23: Master regulators of innate and adaptive immunity", Immunological Reviews, Wiley-Blackwell Publishing, Inc., US, US , (20040101), vol. 202, doi:10.1111/j.0105-2896.2004.00214.x, ISSN 0105-2896, pages 96 - 105, XP002330131
OPPOSITION- LANGRISH et al., "IL -12 and IL -23: master regulators of innate and adaptive immunit y", Immunological reviews, (20040000), vol. 202, doi:10.1111/j.0105-2896.2004.00214.x, pages 96 - 105, XP002330131
OPPOSITION- Yi Chen, Claire L. Langrish, Brent Mckenzie, Barbara Joyce-Shaikh, Jason S. Stumhofer, Terrill McClanahan, Wendy Blumenschein, Tatyana Churakovsa, Justin Low, Leonard Presta, Christopher A. Hunter, Robert A. Kastelein and Daniel J. Cua, "Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis", The Journal of Clinical Investigation, B M J Group, GB, GB , (20060501), vol. 116, no. 5, doi:10.1172/JCI25308, ISSN 0021-9738, pages 1317 - 1326, XP002630082
OPPOSITION- HOOGENBOOM H R, "Overview of Antibody Phage-Display Technology and Its Applications", Antibody-drug conjugates; IN: Methods in Molecular Biology; ISSN 1064-3745; Vol. 263, Humana Press, US, US , (20020101), vol. 178, doi:10.1385/1-59259-240-6:001, ISBN 978-1-62703-541-5, pages 01 - 37, XP009065679
OPPOSITION- KREYMBORG et al., "IL -23: changing the verdict on IL -12 function in inflammatiion and autoimmunity", Expert Opin. Ther. Targets, (20050000), vol. 9, no. 6, doi:10.1517/14728222.9.6.1123, XP055432282
OPPOSITION- KREYMBORG et al., "IL -23: changing the verdict on IL -12 function in inflammation and a utoimmunity", Exp Opin Ther Targets, (20050000), vol. 9, no. 6, doi:10.1517/14728222.9.6.1123, pages 1123 - 1136, XP055432282
OPPOSITION- CONRAD, "Considerations on - display methodology", Combinatorial Chem High Throughput Screening, (20050000), vol. 8, doi:10.2174/1386207053258532, pages 117 - 126, XP008054383
OPPOSITION- CONRAD et al., "Considerations on Antibody-Phage display Methodology", Combinatorial Chemistry & high Throughput Screening, (20050000), vol. 8, no. 2, doi:10.2174/1386207053258532, XP008054383
OPPOSITION- H. Kidoya, Umemura M., Kawabe T., Matsuzaki G., Yahagi A., Imamura R., Suda T., "Fas Ligand Induces Cell-Autonomous IL-23 Production in Dendritic Cells, a Mechanism for Fas Ligand-Induced IL-17 Production", The Journal of Immunology, Williams & Wilkins Co., US, US , (20051215), vol. 175, no. 12, doi:10.4049/jimmunol.175.12.8024, ISSN 0022-1767, pages 8024 - 8031, XP055253644

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents